| Literature DB >> 21813023 |
Eldie Berger1, Michael C Crampton, Nolwandle P Nxumalo, Maureen E Louw.
Abstract
BACKGROUND: Through modification of the flagellin type III secretion pathway of Bacillus halodurans heterologous peptides could be secreted into the medium as flagellin fusion monomers. The stability of the secreted monomers was significantly enhanced through gene-targeted inactivation of host cell extracellular proteases. In evaluating the biotechnological potential of this extracellular secretion system an anti-viral therapeutic peptide, Enfuvirtide, was chosen. Currently, Enfuvirtide is synthesised utilizing 106 chemical steps. We used Enfuvirtide as a model system in an effort to develop a more cost-effective biological process for therapeutic peptide production.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21813023 PMCID: PMC3160875 DOI: 10.1186/1475-2859-10-62
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Bacterial strains and plasmids used in this study
| Strain or plasmid | Relevant characteristics | Source or reference |
|---|---|---|
| Δ | Berger et al (2009) | |
| Δ | This study | |
| Δ | This study | |
| Δ | This study | |
| Δ | This study | |
| (F- | Invitrogen | |
| pSEC194 | CmR, ApR, thermosensitive integration vector | Crampton et al (2007) |
| pNW33N | Bacillus Genetics Stock Centre, (BGSC) Ohio, USA | |
| pSECFliCFFuz | pSEC194, σD promoter, | This study |
| pNWFliCFFuz | pNW33N, σD promoter, | This study |
| pNWNCFFuz | pNW33N, σD promoter, truncated | This study |
| pNWNFFuz | pNW33N, σD promoter, N- terminal | This study |
| pNWCFFuz | pNW33N, σD promoter, ATG, C-terminal | This study |
List of primers, their corresponding nucleotide sequences and application
| Primer name | Nucleotide sequencea | Application |
|---|---|---|
| SpoIVF | CGGA | Spo0A |
| SUpR | CTA | Spo0A |
| SDoF | CTA | Spo0A |
| SDoR | CTA | Spo0A |
| UplytCF | CTC | LytCE |
| UplytCR | CTC | LytCE |
| DolytEF | CTC | LytCE |
| DolytER | CTC | LytCE |
| FlgMF | GTTA | FlgM |
| FMNtR | CTG | FlgM |
| FMCtF | CTG | FlgM |
| FMCR2 | CAT | FlgM |
| ClpUp | GTA | ClpP |
| ClpUpR | GTA | ClpP |
| CDoF | ClpP | |
| CDoR | ClpP | |
| LacF | CTA | AprX |
| AprXR1 | CGA | AprX |
| AprXF2 | CTA | AprX |
| AprXR2 | CTA | AprX |
| CTC | FliC | |
| FliCendR | CGAC | FliC |
| FlagXhoF | GAGA | FLAG tag |
| FuzendR2 | GTCTA | Enfuvirtide |
| NRev | CTTA | N-terminal FliC |
| CFOR | CTAC | C-terminal FliC |
| CstartR | GTCT | C-terminal FliC |
a Restriction enzyme sites are underlined.
Figure 1Schematic representation of the flagellin fusion constructs containing different regions of the FliC protein fused to the FLAG tag and the Enfuvirtide peptide (Fuz) expressed in . The numbers indicate the size (amino acids) of the different fragments of the FliC protein used for the different constructs. The different colour blocks indicate the different regions of the FliC protein: the full-length flagellin protein (FliC1-275), the N-terminal region (FliC1-45) in blue, the C-terminal region (FliC202-275) in yellow and a truncated version with 157 amino acids of the central variable region (grey) deleted (FliCΔ45-275). The red block indicates a FLAG tag and the green block the Enfuvirtide (Fuz) peptide. An enterokinase cleavage site was inserted between the FLAG tag and Enfuvirtide peptide.
Figure 2SDS-PAGE and Western blot analysis of different fractions of . (A) SDS-PAGE (12%) analysis of 16 h crude cell-culture supernatants (20 μl) and intracellular fractions (20 μl) from the different B halodurans strains as indicated above each lane. (B) Western blot analysis of the same samples as in A using Anti-FLAG monoclonal antibodies. The letter S indicates cell-free culture supernatant and I intracellular fraction. (C) Western blot analysis with an antibody to chloramphenicol acetyltransferase as a test for cell lysis. The crude cell-free supernatants (S) are the same as in A and the intracellular fractions are from control strain BhFDL05S (pSECFliCFFuz), lane 1; BhFDL05S (pSEC194), lane 2 and negative control BhFDL05S without plasmid, lane 3. The arrow indicates the expected size for chloramphenicol acetyltransferase (35 kDa). The molecular weight markers in kDa are indicated on the left.
Figure 3Comparison of amount of Enfuvirtide peptide (mg/gdw) produced in the different . An ELISA plate assay using Anti-FLAG antibodies was used to determine the concentration of fusion protein produced in the culture supernatants of the different strains at selected time points. The amount of Enfuvirtide peptide was calculated and presented as mg Enfuvirtide per grams dry weight. The error bars show the ± SD of three separate experiments.
Figure 4SDS-PAGE and Western blot analysis of cell culture supernatants of . (A) SDS-PAGE (15%) analysis of culture supernatants taken from 16 h cultures. The first three lanes each contained crude supernatant (20 μl) and lane 4 (pNWNFFuz) contained concentrated culture supernatant (equivalent to 250 μl of crude supernatant). This was due to relatively low concentrations of the fusion peptide. (B) Western blot analysis of same samples in (A) using Anti-FLAG monoclonal antibodies. (C) Western blot analysis of pNWFliCFFuz (38.2 k Da), pNWNCFFuz (19.8 k Da) and pNWNFFuz (10.5 k Da) with Anti-Enfuvirtide polyclonal antibodies. The amount of sample used for the Western blot was half of that used for the SDS-PAGE gel. Molecular weight markers in kDa are indicated on the left.
Figure 5Comparison of amount of Enfuvirtide peptide (mg/gdw) produced in . The amount of Enfuvirtide peptide was calculated and presented as mg Enfuvirtide per grams dry weight. The error bars show the ± SD of three separate experiments.
Densitometric analysis of the fusion proteins from the Coomassie blue-stained SDS-PAGE gel (mg/L), as compared to ELISA results (mg/gdw)
| Construct name | Fusion protein | Enfuvirtide peptide | Enfuvirtide peptide (mg/gdw) |
|---|---|---|---|
| 18.5 | 1.8 | 0.7 | |
| 32.9 | 3.3 | 1.3 | |
| 61.0 | 13.4 | 2.8 | |
| 2.6 | 1.3 | 0.3 | |
| ND | ND | 0 |
*Enfuvirtide peptide calculated as a percentage of total fusion protein.
**Results quoted as the average of three experiments.